entity

Nrf2 activation

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Nrf2 activation: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

18Connections
5Hypotheses
6Analyses
14Outgoing
4Incoming
0Experiments
7Debates

No AI portrait yet

Outgoing (14)

TargetRelationTypeStr
mitochondrial biogenesisactivatesprocess0.90
neurodegenerative diseasesprotective_againstdisease0.90
cardiovascular mortalityrisk_factor_forphenotype0.90
ALSassociated_withdisease0.70
AD pathologyprotective_againstdisease0.70

Incoming (4)

SourceRelationTypeStr
Elevated KEAP1inhibitsprotein0.90
Dimethyl fumarateactivatesdrug0.90
p62 impairmentinhibitsmechanism0.70
p62-mediated autophagy impairmentinhibitsprocess0.70

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
NRF2 Activation Provides Neuroprotection Across ALS, AD, and 0.710 neurodegeneration Test Preregistration Analysis
Endothelial NRF2 Activation as a Master Switch for Post-CA B 0.689 neurodegeneration View
HBOT at 1.5 ATA for 60 min induces hormetic response via Nrf 0.640 neurodegeneration What are the optimal oxygen pressure, du
oxLDL/LOX-1/ROS Signaling Induces P2RY12 via Nrf2 Activation 0.550 neurodegeneration What determines P2RY12 receptor expressi
NRF2 Activation to Counteract Oxidative Stress from RGS6 Def 0.518 neurodegeneration Does RGS6 upregulation or D2 autorecepto

Mentioning Analyses (6)

Scientific analyses that reference this entity

Test Preregistration Analysis

neurodegeneration | 2026-04-27 | 7 hypotheses Top: 0.710

Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron

neurodegeneration | 2026-04-16 | 7 hypotheses Top: 0.680

Gene Regulatory Network Inference in Alzheimer's Disease

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.661

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.604

How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.521

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (7)

Multi-agent debates referencing this entity

Test question for preregistration

active · Rounds: 4 · Score: 0.77 · 2026-04-28

Which transcription factors drive the gene regulatory networks that distinguish

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

The debate revealed a critical gap: while PINK1/PARKIN deficiency correlates wit

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron

closed · Rounds: 5 · Score: 0.59 · 2026-04-16

Is REST the master regulator of neuronal vulnerability in AD, or is it one of se

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The observation that salsalate and diflunisal decrease both AD and TBI incidence

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper d

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Related Research

Hypotheses and analyses mentioning Nrf2 activation in their description or question text

No additional research found